We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




A Protein Is Unusual Tumor Suppressor

By Biotechdaily staff writers
Posted on 22 Feb 2006
Cancer researchers have shown that the tumor-suppressing protein REG-gamma activates the proteasome-mediated destruction of the protein product of the powerful oncogene steroid receptor coactivator-3 (SRC-3).

Investigators at Baylor College of Medicine (Houston, TX, USA) used RNA interference (RNAi) technology to "knockdown” the activity of REG-gamma. More...
Their results published in the January 27, 2006, issue of Cell showed that reduction of REG-gamma activity allowed the overexpression of SRC-3 with subsequent stimulation of tumor cell growth. In vitro proteasome proteolysis assays using purified REG-gamma, SRC-3, and the 20S proteasome demonstrated that REG-gamma promoted the degradation of SRC-3 in an ubiquitin- and ATP-independent manner.

"It is another intervention point where one can now attack tumors. It is especially important for endocrine tumors such as those of the breast, prostate, ovary, and pituitary gland,” said senior author Dr. Bert O'Malley, professor of molecular and cellular biology at Baylor College of Medicine. "This is an important pathway for SRC3 degradation that has never been described. This molecule does not require ubiquitin or an energy source, it is a really strange and different molecule for that reason.”



Related Links:
Baylor College of Medicine

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.